Oncology Business Management | Specialty

FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma

November 2nd 2017

The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.

CMS Reins in Spending Under 340B, Garnering Praise, Criticism

November 2nd 2017

A newly announced CMS policy to redistribute savings under the 340B Drug Discount Program so that Medicare beneficiaries save money on copayments has garnered a mixture of praise and criticism from supporters and critics of the program.

Clinical Impact of Chronic Low-Grade Nausea Is Woefully Underestimated

November 1st 2017

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Balancing Family With Career Goals During an Oncology Fellowship

November 1st 2017

Successfully attaining our goals in fellowship is demanding. They are accomplished by establishing work/life balance.

Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL

October 31st 2017

Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.

A "Perfect Storm" Drove Independent to Merge With Hospital

October 31st 2017

As many hard-pressed physician practices have been doing in the present healthcare environment, our oncology practice also had to take a hard look at our operational design, strategy for the future, and sustainability.

Novartis to Add Lutathera to Portfolio in Planned $3.9-Billion Deal

October 30th 2017

Novartis has announced a planned $3.9-billion acquisition of Advanced Accelerator Applications, a radiopharmaceutical company that develops, produces, and commercializes Molecular Nuclear Medicines.

The Quirky Way Physicians Are Paid

October 29th 2017

In community oncology, the complexity and cost of therapy and therapy administration have caused the cost of delivering a service to rise disproportionately relative to actual payment.

CMS Claims Data Provide Glimpse of True Cost Picture

October 27th 2017

As the Oncology Care Model practices work to reduce Medicare’s overall spending on those patients and to earn shared savings payments, the data are providing them with an unprecedented full picture of the extent and cost of care.

Dr. Blau on a Research-Based Approach to Meet OCM Requirements

October 27th 2017

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 27th 2017

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

Now Is the Time to Address the Looming Shortage of Oncologists

October 23rd 2017

The Community Oncology Alliance has embarked on a journey to educate and inform the men and women undertaking hematology/oncology fellowships across the country about the employment choices awaiting them.

There Was No Single "Magic Bullet" That Made the OCM Work

October 23rd 2017

North Star Lodge of Yakima, Washington, found that making the Oncology Care Model work involved solving a long series of problems.

Follicular Lymphoma: Audience Q&A

October 21st 2017

Follicular Lymphoma: Complexities in Combinations

October 21st 2017

Follicular Lymphoma: Considering All Novel Agents

October 21st 2017

FL: The Impact of Data from Clinical Trials

October 21st 2017

Follicular Lymphoma: Challenges in Moving Forward

October 21st 2017

Follicular Lymphoma: Optimizing Copanlisib

October 21st 2017

Follicular Lymphoma: Defining Copanlisib

October 21st 2017